Free Trial

Medtronic (NYSE:MDT) Downgraded by Wall Street Zen to Hold

Medtronic logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Medtronic from “Buy” to “Hold.” Despite the change, analysts overall rate the stock “Moderate Buy,” with a consensus price target of $102.88.
  • Medtronic reported quarterly EPS of $1.45, topping the $1.39 consensus estimate, and revenue of $9.76 billion, above expectations and up 13.7% year over year.
  • The stock opened at $102.84, near its 12-month high of $106.33. Company insiders sold a combined 61,903 shares over the last quarter.
  • Five stocks to consider instead of Medtronic.

Medtronic (NYSE:MDT - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Monday, Wall Street Zen reports.

A number of other research firms have also weighed in on MDT. Deutsche Bank reiterated a "hold" rating and issued a $92.00 price target on shares of Medtronic in a research report on Thursday, September 3rd. Stifel Nicolaus lifted their target price on shares of Medtronic from $80.00 to $95.00 and gave the company a "hold" rating in a research note on Wednesday, September 2nd. Robert W. Baird upped their target price on shares of Medtronic from $91.00 to $100.00 and gave the stock a "neutral" rating in a report on Wednesday, September 2nd. Bank of America increased their price target on Medtronic from $95.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, September 2nd. Finally, BTIG Research decreased their price target on Medtronic from $100.00 to $99.00 and set a "buy" rating on the stock in a report on Monday, October 12th. Eighteen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medtronic presently has an average rating of "Moderate Buy" and a consensus price target of $102.88.

View Our Latest Report on MDT

Medtronic Stock Down 0.0%

MDT stock opened at $102.84 on Monday. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $131.54 billion, a P/E ratio of 25.33, a PEG ratio of 2.41 and a beta of 0.56. The business's 50-day moving average price is $93.72 and its 200-day moving average price is $88.47.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm's revenue was up 13.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts forecast that Medtronic will post 5.98 EPS for the current year.

Insider Transactions at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the firm's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares of the company's stock, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Geoffrey Martha sold 50,000 shares of Medtronic stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Entropy Technologies LP lifted its position in shares of Medtronic by 23.2% in the third quarter. Entropy Technologies LP now owns 22,775 shares of the medical technology company's stock worth $1,965,000 after buying an additional 4,291 shares in the last quarter. Jump Financial LLC boosted its stake in Medtronic by 56.0% during the third quarter. Jump Financial LLC now owns 170,816 shares of the medical technology company's stock valued at $14,740,000 after buying an additional 61,288 shares during the last quarter. Perennial Investment Advisors LLC boosted its stake in Medtronic by 33.2% during the third quarter. Perennial Investment Advisors LLC now owns 5,568 shares of the medical technology company's stock valued at $480,000 after buying an additional 1,388 shares during the last quarter. L2 Asset Management LLC boosted its stake in Medtronic by 4.3% during the third quarter. L2 Asset Management LLC now owns 7,653 shares of the medical technology company's stock valued at $660,000 after buying an additional 313 shares during the last quarter. Finally, Financial Advisors Network Inc. grew its holdings in Medtronic by 12.7% during the 3rd quarter. Financial Advisors Network Inc. now owns 5,440 shares of the medical technology company's stock valued at $469,000 after buying an additional 613 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

About Medtronic

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Stories

Analyst Recommendations for Medtronic (NYSE:MDT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medtronic Right Now?

Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines